Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Studies of empagliflozin and dapagliflozin have shown to reduce cardiovascular risk, indicating a class effect for heart failure patients.
Read More »Empagliflozin Benefit in Heart Failure, With or Without Diabetes
Using SGLT-2 Inhibitors to Significantly Reduce AFib
Diabetes causes metabolic changes that promote oxidative stress within the heart, resulting in changes that can impede its electrical signaling.
Read More »PCOS Increases Risk For CVD
Insulin resistance and weight gain are common with PCOS and impact multiple CVD risk factors.
Read More »The Role of Dapagliflozin in Patients with Type 2 Diabetes and Atrial Fibrillation
A post hoc analysis of the DECLARE-TIMI 58 trial may provide a new compelling indication for dapagliflozin.
Read More »Major Reduction in Risk of Heart Attacks in Patients with Diabetes
Initiating the right medications upon diabetes diagnosis can help mitigate heart attack risk.
Read More »Real-World Data on the Benefit of Sodium Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Risk
SGLT2 inhibitors compared to DPP-4 inhibitors: which showed a favorable effect on MACE?
Read More »Cardiovascular Outcomes of Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease
Finerenone, which treats CKD, may also help to reduce cardiac failure in type 2.
Read More »Cognitive Decline a Result of Diabetes and Hypertension
The CARDIA study explored the link to the decline in cognitive abilities in diseases like Alzheimer's and Parkinson's in middle-aged populations.
Read More »Can Patients with Stable Coronary Disease and Diabetes Benefit from Ticagrelor?
Cardiovascular events and diabetes go hand in hand, but what if there’s already a drug out there to lower the risk of those events?
Read More »Effect of Lifestyle Intervention on Heart Failure and Myocardial Infarction in T2D
A study based on the Look AHEAD trial examined how weight loss and physical activity impact the risk of HF, MI, and T2DM.
Read More »